Health Professional Radio - Podcast

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses the recent European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) positive opinion on Merck's KEYTRUDA® (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for advanced renal cell carcinoma. Opinion granted based on data from the Phase 3 KEYNOTE-426 Trial. #RenalCellCarcinoma #AdvancedRenalCellCarcinoma #AdvancedRenalCellCarcinomaTreatment Visit our website www.healtprofessionalradio.com.au Follow us on our social media channels Facebook: https://www.facebook.com/hprfm/ Twitter: https://twitter.com/HealthProRadio Google+: https://plus.google.com/+HealthProfes... Pinterest: https://www.pinterest.com/HealthProRa... Linkedin: https://www.linkedin.com/company/heal... Instagram: https://www.instagram.com/healthprofe... Subscribe to our podcast channels Soundcloud: https://soundcloud.com/healthprofessi... Itunes: https://itunes.apple.com/nz/podcast/h... Support us on Patreon https://www.patreon.